A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension
A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.
Key Inclusion Criteria
Key Exclusion Criteria
Other protocol-defined inclusion/exclusion criteria may apply
novartis.email@novartis.com1-888-669-6682
+41613241111
Phoenix, Arizona 85006, United States
San Antonio, Texas 78229-3900, United States
North York, Ontario M6A 2C8, Canada
Itabashi Ku, Tokyo 1730015, Japan
Shinjuku Ku, Tokyo 160-0023, Japan
+1 949 753 1663#208
+1 561 968 2933
+1 813 345 8210
+1 561 209 2400
+1 913 588 0555
+1 978 462 9571
+1 417 841 3643
+1 702 483 6025
+1 215 957 9250 #57
+1 210 567 8229